Authors
Latest:
Medicare Inpatient and Postdischarge Outcomes of Elective Percutaneous Coronary InterventionsAn understanding of risk-adjusted outcomes for percutaneous coronary interventions for both inpatient and 90-day postdischarge events is necessary for the redesign of care outcomes.
Latest:
Outpatient Parenteral Antimicrobial Therapy at Large Veterans Administration Medical CenterOutpatient parenteral antimicrobial therapy was successfully delivered in our facility despite significant comorbidity and geographic limitations.
Latest:
Systemic Treatments for Advanced Prostate Cancer: Relationship Between Health Insurance Plan and Treatment CostsThe authors examine how insurer and patient out-of-pocket payments for advanced prostate cancer differ by drug and health plan type and describe the relationship between these payments and utilization.
Latest:
Routine Pre-cesarean Staphylococcus aureus Screening and Decolonization: A Cost-Effectiveness AnalysisRoutinely screening pregnant women for Staphylococcus aureus colonization and decolonizing carriers before cesarean delivery are unlikely to be cost-effective under current epidemiologic circumstances.
Latest:
Beyond Regulatory Requirements: Designing ACO Websites to Enhance Stakeholder EngagementThe authors describe best practices for Web design in the accountable care organization space in order to enhance engagement with patients and providers.
Latest:
A Systematic Review of Value-Based Insurance Design in Chronic DiseasesValue-based insurance design for prescription drug coverage increases drug adherence in patients with chronic disease, though their effect on clinical outcomes and health spending remain uncertain.
Latest:
Electronic Health Record Feedback to Improve Antibiotic Prescribing for Acute Respiratory InfectionsAn electronic health record–based feedback program, the Acute Respiratory Infection Quality Dashboard, did not lead to an overall change in antibiotic prescribing in primary care.
Latest:
Perspective: FDA/CMS Parallel Review Advances Coverage for Cancer Comprehensive Genomic ProfilingAuthors from Foundation Medicine explain the regulatory path that led to approval of FoundationOne CDx.
Latest:
Does Comparing Cesarean Delivery Rates Influence Women’s Choice of Obstetric Hospital?This randomized controlled trial finds that a hospital cesarean delivery rate comparison tool affects women’s perceptions but not where they choose to deliver.
Latest:
Targeting a High-Risk Group for Fall Prevention: Strategies for Health PlansThis study evaluates different strategies to identify high fall risk among community-dwelling elders using a combination of easily obtainable administrative data and patient screening questions.
Latest:
Improvements in Access and Care Through the Affordable Care ActAffordable Care Act exchange enrollees in California and Colorado reported significant improvements in access to care and fewer barriers to receiving care due to costs.
Latest:
A Population-Based Assessment of Proton Beam Therapy Utilization in CaliforniaThis population-based analysis of patients with cancer in California found significant differences in proton beam therapy use by health insurance type, race/ethnicity, and socioeconomic status.
Latest:
Health Plan Use of Immunization Information Systems for Quality MeasurementHealth plans may benefit from using a state immunization information system as the primary data source for HEDIS and physician incentive and quality programs.
Latest:
Cost Utility of Hub-and-Spoke Telestroke Networks From Societal PerspectiveA cost-utility analysis of a hub-and-spoke telestroke network showed that it was economically dominant over routine care.
Latest:
Cost Burden of Hepatitis C Virus Treatment in Commercially Insured PatientsRates of hepatitis C virus (HCV) treatment in a commercially insured population doubled after availability of new direct-acting antivirals. Member out-of-pocket spending was kept low while the health plan bore 99% of spending on HCV medications.
Latest:
Cost-effectiveness of Brentuximab Vedotin With Chemotherapy in Treatment of CD30-Expressing PTCLAn economic model based on the ECHELON-2 trial demonstrated cost-effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma (PTCL).
